Nov. 19, 2026 Khetpal is a preventive cardiologist and assistant professor of medicine at the Northwestern University Feinberg School of Medicine. He writes The Workup, a STAT column about cardiology. At the American Heart Association’s recent annual meeting, the overarching theme coming from the center stage, bathed in Pantone red, was one of high-profile neutral findings. As I listened to the results of the STREAM trial — which found that older adults without a history of heart attacks or strokes who stopped taking statins didn’t have significantly different outcomes from those who continued taking them — I jotted down that the study continued the theme. But as the Kaplan-Meier curves were cast onto the screen, something felt off: The curves diverged, rather than stayed together. Theoretically, this scenario can happen in noninferiority studies, where researchers are testing whether an intervention offers similar outcomes compared with a standard. De-prescribing statins in this group, by the expectations set by researchers at the beginning of STREAM, was technically noninferior, but nevertheless, still inferior. The patients randomized to stop taking their statin did worse compared with those who continued. Even the trial’s data safety monitoring board suggested that patients who have stopped their statins should talk to their doctors about resuming their medications. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe
Opinion: STAT+: I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.